Horst Dürkop

5.2k total citations · 2 hit papers
58 papers, 3.9k citations indexed

About

Horst Dürkop is a scholar working on Immunology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Horst Dürkop has authored 58 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Immunology, 27 papers in Pathology and Forensic Medicine and 18 papers in Oncology. Recurrent topics in Horst Dürkop's work include Lymphoma Diagnosis and Treatment (26 papers), NF-κB Signaling Pathways (10 papers) and Immune Cell Function and Interaction (9 papers). Horst Dürkop is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), NF-κB Signaling Pathways (10 papers) and Immune Cell Function and Interaction (9 papers). Horst Dürkop collaborates with scholars based in Germany, United States and Italy. Horst Dürkop's co-authors include Harald Stein, Stefano Pileri, Brunangelo Falini, Florian Eitelbach, Ute Latza, Michael Hummel, Hans‐Dieter Foss, Brian Seed, Leonardo Flenghi and Karen Pulford and has published in prestigious journals such as Cell, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Horst Dürkop

58 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features

2000 626 citations Harald Stein, Horst Dürkop et al. profile →
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

1992 559 citations Horst Dürkop, Ute Latza et al. Cell profile →

Peers

Countries citing papers authored by Horst Dürkop

Since Specialization

Citations

This map shows the geographic impact of Horst Dürkop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Horst Dürkop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Horst Dürkop more than expected).

Fields of papers citing papers by Horst Dürkop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Horst Dürkop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Horst Dürkop. The network helps show where Horst Dürkop may publish in the future.

Co-authorship network of co-authors of Horst Dürkop

This figure shows the co-authorship network connecting the top 25 collaborators of Horst Dürkop. A scholar is included among the top collaborators of Horst Dürkop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Horst Dürkop. Horst Dürkop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model 2018 ·Journal of Cancer Research and Clinical Oncology ·Hans D. Menssen, (unknown), Ulrike Erben, Dario Neri, Burkhard Hirsch, Horst Dürkop	20
2	A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies 2015 ·Leukemia ·H Stein, Roshanak Bob, Horst Dürkop, Christian Erck, (unknown), (unknown), Henri Martens, Andreas Röth, Anna Streubel	22
3	Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient 2013 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Paola Anna Erba, Burkhard Hirsch, Emilio Bombardieri, Leonardo Giovannoni, Dario Neri, Horst Dürkop, Hans D. Menssen	23
4	Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells 2011 ·Laboratory Investigation ·Osamu Suzuki, Burkhard Hirsch, Masafumi Abe, Horst Dürkop, Harald Stein	8
5	Resistance of Cutaneous Anaplastic Large-Cell Lymphoma Cells to Apoptosis by Death Ligands Is Enhanced by CD30-Mediated Overexpression of c-FLIP 2009 ·Journal of Investigative Dermatology ·Frank Braun, Burkhard Hirsch, Nadya Al‐Yacoub, Horst Dürkop, Chalid Assaf, Marshall E. Kadin, Wolfram Sterry, Jürgen Eberle	23
6	Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo 2009 ·Current Drug Targets ·Burkhard Hirsch, (unknown), (unknown), Christoph Loddenkemper, Silvia Bulfone‐Paus, H Stein, Horst Dürkop	8
7	CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells 2008 ·American Journal Of Pathology ·Burkhard Hirsch, Michael Hummel, Stefan Bentink, (unknown), Rainer Spang, Raphaël Zollinger, Harald Stein, Horst Dürkop	54
8	Differential Expression of TRAF1 Aids in the Distinction of Cutaneous CD30-Positive Lymphoproliferations 2007 ·Journal of Investigative Dermatology ·Chalid Assaf, Burkhard Hirsch, Florian Wagner, Lothar Lucka, (unknown), Sylke Gellrich, Ansgar Lukowsky, Wolfram Sterry, Harald Stein, Horst Dürkop	19
9	A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice 2006 ·Journal of Controlled Release ·Hendrik Fuchs, Christopher Bachran, Tongyu Li, Iring Heisler, Horst Dürkop, Mark Sutherland	34
10	Blocking IL-15 Prevents the Induction of Allergen-Specific T Cells and Allergic Inflammation In Vivo 2005 ·The Journal of Immunology ·René Rückert, Katja Brandt, Armin Braun, Heinz-Gerd Hoymann, Udo Herz, Vadim Budagian, Horst Dürkop, Harald Renz, Silvia Bulfone‐Paus	60
11	mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma 2005 ·Leukemia Research ·Philipp B. Staber, Christa Noehammer, Horst Dürkop, Silvia Schauer, Lukas Kenner, Werner Linkesch, Gerald Höefler	12
12	Bisphosphonate und Osteonekrosen im Kieferbereich 2005 ·Mund- Kiefer- und Gesichtschirurgie ·(unknown), Harm Peters, P. A. Reichart, Horst Dürkop	27
13	Human CD30: Structural implications from epitope mapping and modeling studies 2003 ·Journal of Molecular Recognition ·Liying Dong, Martin Hülsmeyer, Horst Dürkop, Hinrich P. Hansen, Jens Schneider‐Mergener, Andreas Ziegler, Barbara Uchańska‐Ziegler	19
14	CS‐1, a novel c‐kit^hi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity 2003 ·International Journal of Cancer ·Ulrike Erben, Eckhard Thiel, (unknown), Claudia Schoch, Iduna Fichtner, Horst Dürkop, Michael Notter	2
15	The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter 2000 ·The Journal of Pathology ·Horst Dürkop, Martin H. Oberbarnscheidt, Ute Latza, Silvia Bulfone‐Paus, Burkhard Hirsch, Thomas Pohl, Hans Krause, Michael Hummel, Harald Stein	12
16	Three New Types of Apaf-1 in Mammalian Cells 1999 ·Biochemical and Biophysical Research Communications ·Corinna Hahn, Burkhard Hirsch, (unknown), Horst Dürkop, Harald Stein	12
17	The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen 1994 ·European Journal of Immunology ·Ute Latza, Horst Dürkop, Susanne Schnittger, (unknown), Florian Eitelbach, Michael Hummel, Christa Fonatsch, Harald Stein	109
18	PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. 1993 ·PubMed ·Brunangelo Falini, Leonardo Flenghi, Stefano Pileri, Marcello Gambacorta, Barbara Bigerna, Horst Dürkop, Florian Eitelbach, J. Thiele, Roberta Pacini, Antonio Cavaliere	257
19	Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease breakdown → 1992 ·Cell ·Horst Dürkop, Ute Latza, Michael Hummel, Florian Eitelbach, Brian Seed, Harald Stein	559
20	Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin 1992 ·The Lancet ·Brunangelo Falini, Leonardo Flenghi, Franco Aversa, Giuliana Barbabietola, MF Martelli, (unknown), Pier Luigi Tazzari, (unknown), H. Stein, Horst Dürkop, Giovanni Pizzolo, Andrea Bolognesi, Fiorenzo Stirpe, Elena Sabattini, Stefano Pileri	171

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact